. registration with Food and Drug Administration (FDA), trademark permission, product and packaging design, and brand building etc. to customers who are business operator in skin cares and cosmetics. In addition
international sales declined dramatically at 46.03% compared to the same period of the previous year. One of the issues was the delayed product delivery after the license was issued from China Food and Drug
granted a license from China Food and Drug Administration (CFDA) during the beginning of 2018 as the Company had to redesign and adjust product packaging according to the granted license as well as change
issued from China Food and Drug Administration (CFDA) at the beginning of 2018 as the Company had to redesign its packaging to comply with the requirements of the license and adjust its sales structures
, e.g., supermarket, food and restaurants (only for takeaway), drug stores. Online sales continued to grow remarkably by 150.0% YoY. Gross profit margin from sale of goods improved outstandingly to
that included the revenue from furniture business by growing 11 percent from domestic sales. At the present, the proportion of domestic sales is 47 percent of total revenue from sale. In addition, other
-Tepharak in the present, No. 15/2014 on 13 June 2014. Then, on 24 October 2018, the Company had cancelled land allocation request. Yearly 2019, the Treasury considered that City Plus would be developed to
quarter of 2017 Attention: The President The Stock Exchange of Thailand The Company wishes to present the Management Discussion & Analysis (MD&A) on the operating and financial status for the 2nd quarter of
in the separate financial statements. As the consolidated present the impairment on investment by equity method. Yours sincerely, ( Mr. Chuangchai Nawongs) Chief Executive Officer and President
President The Stock Exchange of Thailand The Company wishes to present the Management Discussion & Analysis (MD&A) on the operating and financial status for the 3rd quarter of 2017. The MD&A would enable the